FIBROGEN INCKYNBEarnings & Financial Report
FibroGen Inc. is a biopharmaceutical firm developing and commercializing innovative therapies for unmet medical needs, targeting fibrotic diseases, anemia and cancer. Its lead product roxadustat is approved in multiple markets including China and Japan, serving patients across key therapeutic segments.
KYNB Q1 FY2024 Key Financial Metrics
Revenue
$25.4M
Gross Profit
$4.0M
Operating Profit
$-49.2M
Net Profit
$-32.9M
Gross Margin
15.9%
Operating Margin
-193.9%
Net Margin
-129.8%
YoY Growth
-29.9%
EPS
$-0.33
FIBROGEN INC Q1 FY2024 Financial Summary
FIBROGEN INC reported revenue of $25.4M (down 29.9% YoY) for Q1 FY2024, with a net profit of $-32.9M (up 57.1% YoY) (-129.8% margin). Cost of goods sold was $21.3M, operating expenses totaled $53.2M.
Key Financial Metrics
| Total Revenue | $25.4M |
|---|---|
| Net Profit | $-32.9M |
| Gross Margin | 15.9% |
| Operating Margin | -193.9% |
| Report Period | Q1 FY2024 |
Revenue Breakdown
FIBROGEN INC Q1 FY2024 revenue of $25.4M breaks down across 2 segments, led by Drug Product Revenue at $24.5M (96.5% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Drug Product Revenue | $24.5M | 96.5% |
| Other | $878.0K | 3.5% |
FIBROGEN INC Annual Revenue by Year
FIBROGEN INC annual revenue history includes year-by-year totals (for example, 2023 revenue was $46.8M).
FIBROGEN INC Quarterly Revenue & Net Profit History
FIBROGEN INC results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2024 | $25.4M | -29.9% | $-32.9M | -129.8% |
| Q4 FY2023 | $-73.8M | -314.8% | $-56.2M | 76.2% |
| Q3 FY2023 | $40.1M | +155.1% | $-63.6M | -158.5% |
| Q2 FY2023 | $44.3M | +48.7% | $-87.7M | -197.8% |
| Q1 FY2023 | $36.2M | -40.6% | $-76.7M | -212.1% |
| Q4 FY2022 | $34.4M | +107.7% | $-66.2M | -192.6% |
| Q3 FY2022 | $15.7M | -89.9% | $-91.7M | -582.5% |
| Q2 FY2022 | $29.8M | +22.3% | $-72.6M | -243.7% |
Income Statement
| Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $29.8M | $15.7M | $34.4M | $36.2M | $44.3M | $40.1M | $-73.8M | $25.4M |
| YoY Growth | 22.3% | -89.9% | 107.7% | -40.6% | 48.7% | 155.1% | -314.8% | -29.9% |
Balance Sheet
| Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $686.8M | $608.8M | $610.1M | $538.5M | $515.1M | $460.4M | $423.5M | $365.9M |
| Liabilities | $563.0M | $562.6M | $611.6M | $567.4M | $575.4M | $575.6M | $585.7M | $552.0M |
| Equity | $103.8M | $26.3M | $-21.4M | $-48.9M | $-102.3M | $-157.2M | $-204.2M | $-228.1M |
Cash Flow
| Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-33.1M | $-51.9M | $-52.5M | $-101.6M | $-110.6M | $-84.5M | $-18.3M | $-59.3M |